Joincare Pharmaceutical Group's subsidiary, Injection JP-1366, has been approved to conduct clinical trials.

Joincare Pharmaceutical Group Inc. (600380.SH) announced that its subsidiary, Livzon Pharmaceutical Group Inc., has received approval from the National Medical Products Administration for a clinical trial of injection JP-1366. JP-1366 is a new type of potassium ion competitive acid blocker (P-CAB), which works by competitively binding to the potassium ion binding site of H+/K+-ATPase in gastric wall cells, inhibiting acid secretion. P-CAB has the characteristics of rapid onset, good acid suppression, long-lasting effects, low individual differences, and minimal drug interactions. The indication for the clinical trial of injectable JP-1366 is bleeding peptic ulcer.